» Articles » PMID: 29144739

Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?

Overview
Journal J Med Chem
Specialty Chemistry
Date 2017 Nov 17
PMID 29144739
Citations 129
Authors
Affiliations
Soon will be listed here.
Abstract

Targeted protein degradation, using bifunctional small molecules (Protacs) to remove specific proteins from within cells, has emerged as a novel drug discovery strategy with the potential to offer therapeutic interventions not achievable with existing approaches. In this Perspective, the brief history of the field is surveyed from a drug discovery perspective with a focus on the key advances in knowledge which have led to the definition and exemplification of protein degradation concepts and their resulting applications to medicine discovery. The approach has the potential to bring disruptive change to drug discovery; the many potential advantages and outstanding challenges which lie ahead of this technology are discussed.

Citing Articles

Targeting GOF p53 and c-MYC through LZK Inhibition or Degradation Suppresses Head and Neck Tumor Growth.

Funk A, Katerji M, Afifi M, Nyswaner K, Woodroofe C, Edwards Z bioRxiv. 2024; .

PMID: 39605563 PMC: 11601640. DOI: 10.1101/2024.11.19.623840.


Self-assembled PROTACs enable protein degradation to reprogram the tumor microenvironment for synergistically enhanced colorectal cancer immunotherapy.

Lu X, Jin J, Wu Y, Lin J, Zhang X, Lu S Bioact Mater. 2024; 43:255-272.

PMID: 39386219 PMC: 11461841. DOI: 10.1016/j.bioactmat.2024.09.022.


Caged aminoluciferin probe for bioluminescent immunoproteasome activity analysis.

Loy C, Trader D RSC Chem Biol. 2024; 5(9):877-883.

PMID: 39211472 PMC: 11352960. DOI: 10.1039/d4cb00148f.


Inducing Receptor Degradation as a Novel Approach to Target CC Chemokine Receptor 2 (CCR2).

Ortiz Zacarias N, Roth S, Broekhuis J, van der Es D, Moreau K, Heitman L Int J Mol Sci. 2024; 25(16).

PMID: 39201670 PMC: 11354370. DOI: 10.3390/ijms25168984.


Targeted protein degradation in hematologic malignancies: clinical progression towards novel therapeutics.

Feng Y, Hu X, Wang X Biomark Res. 2024; 12(1):85.

PMID: 39169396 PMC: 11340087. DOI: 10.1186/s40364-024-00638-1.